3 Drug Discovery Services, Branded Formulations and Contract Manufacturing Stocks With a Strong Future Roadmap: Sai Life Sciences, Eris Lifesciences and Innova Captab
- October 21, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Sai Life Sciences, Eris Lifesciences and Innova Captab: ROE of 12.9% to 15.9% and FY22 to FY26 revenue CAGR of 19.5% to 25.7%. Prices as of 20 Oct 2026.
Quick Answer
The three pharma services stocks to watch are Sai Life Sciences, Eris Lifesciences and Innova Captab. Their return on equity ranges from 12.9% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 19.5% to 25.7%. Eris Lifesciences has the highest return on equity at 15.9%, while Sai Life Sciences has the fastest revenue growth at 25.7% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.
Pharma services stocks give investors a way to follow medicine development and manufacturing without relying on one drug. Sai Life Sciences, Eris Lifesciences and Innova Captab cover drug discovery and development services, branded formulations for chronic care and contract manufacturing.
This list covers three pharma services stocks with complete current figures: Sai Life Sciences, Eris Lifesciences and Innova Captab. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma Services Stocks?
Pharma services stocks are listed companies that earn from research, development and manufacturing work for drug makers, or from branded medicines sold to doctors. Their results track customer programmes, prescription growth and plant utilisation.
Pharma Services Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Sai Life Sciences | 1,395.9 | 29,679 | 82.0 | 36.0 | 14.1 | 0.12 |
| Eris Lifesciences | 1,120.4 | 15,618 | 23.5 | 36.0 | 15.9 | 0.60 |
| Innova Captab | 1,001.7 | 5,736 | 37.2 | 36.0 | 12.9 | 0.32 |
On valuation, Eris Lifesciences trades at a P/E below the industry P/E, while Sai Life Sciences and Innova Captab trade above it, which reflects the growth the market already expects. Readers comparing pharma services stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Pharma Services Stocks Have a Strong Roadmap in India?
Pharma services stocks have a strong roadmap in India because global drug makers are widening their use of Indian partners, and domestic demand for chronic therapies keeps growing.
- Outsourcing trend. Drug makers outsource discovery, development and manufacturing to cut cost and time.
- Chronic therapy growth. Diabetes, heart and other long-term conditions give branded drugs repeat demand.
- Integrated offer. Companies that cover several stages keep customers for longer.
Why Sai Life Sciences Features Among These Pharma Services Stocks
Among the pharma services stocks on this list, Sai Life Sciences is a Hyderabad-based contract research, development and manufacturing organisation that works with global pharma and biotech companies from discovery through commercial supply.
The company has a return on equity of 14.1%, a debt to equity ratio of 0.12 and a market capitalisation of Rs 29,679 crore. The stock trades at a P/E of 82.0, above the industry P/E of 36.0.
Revenue rose from Rs 898 crore in FY22 to Rs 2,242 crore in FY26, a compound annual growth rate of 25.7%. Net profit grew from Rs 170 crore in FY25 to Rs 349 crore in FY26, a rise of 105.1%. In the June 2026 quarter, revenue grew 10.2% year on year to Rs 558 crore, while net profit rose 21.2% to Rs 73.3 crore.
Roadmap: The roadmap is built on adding development and manufacturing capacity and moving more projects from discovery into late-stage and commercial supply. Customers tend to stay with a partner across the drug life cycle, which creates a durable order pipeline.
What to watch: Monitor project conversion from development to commercial stages and customer concentration.
Why Eris Lifesciences Features Among These Pharma Services Stocks
Among the pharma services shares on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.
Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%.
In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.
Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.
What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.
Why Innova Captab Features Among These Pharma Services Stocks
Among the three companies on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.
In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%.
Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.
Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.
What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.
Sai Life Sciences vs Eris Lifesciences vs Innova Captab on Key Financials
The table below sets the three pharma services stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Sai Life Sciences | 898 | 2,242 | 25.7% | 349 | 15.6% |
| Eris Lifesciences | 1,373 | 3,137 | 22.9% | 648 | 20.6% |
| Innova Captab | 803 | 1,637 | 19.5% | 141 | 8.6% |
Eris Lifesciences posts the highest return on equity in this group at 15.9%. Eris Lifesciences has the largest FY26 revenue at Rs 3,137 crore, and Sai Life Sciences shows the fastest revenue growth with a 25.7% compound annual rate. A useful habit with pharma services stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Sai Life Sciences | 506 | 558 | 10.2% |
| Eris Lifesciences | 776 | 876 | 12.9% |
| Innova Captab | 356 | 473 | 32.8% |
Key Risks to Check Before Investing in Pharma Services Stocks
Every theme carries risks that deserve a check before any decision. For these pharma services stocks, the main points are: Long-term pharma services shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Customer concentration. A few large customers can account for much of the revenue.
- Regulatory audits. Plant inspections can affect supply and approvals.
- Prescription trends. Branded sales depend on doctor preference and competing launches.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma services stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma Services Stocks
Pharma services stocks reward investors who study customer relationships, plant capacity and therapy mix. Sai Life Sciences, Eris Lifesciences and Innova Captab each show a different route to growing earnings. Based on the 20 October 2026 close, Sai Life Sciences trades at Rs 1,395.9, Eris Lifesciences at Rs 1,120.4 and Innova Captab at Rs 1,001.7. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pharma services stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pharma services stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma services stocks?
Ans. Pharma services stocks are listed companies that earn from research, development and manufacturing work for drug makers, or from branded medicines sold to doctors. Their results track customer programmes, prescription growth and plant utilisation. This list looks at three of them, Sai Life Sciences, Eris Lifesciences and Innova Captab, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.
Which pharma services stocks are covered in this list?
Ans. This list covers Sai Life Sciences, Eris Lifesciences and Innova Captab. Based on the 20 October 2026 close, Sai Life Sciences traded at Rs 1,395.9, Eris Lifesciences at Rs 1,120.4 and Innova Captab at Rs 1,001.7. Their return on equity ranges from 12.9% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 19.5% to 25.7%.
Why do pharma services stocks have a strong future roadmap in India?
Ans. Pharma services stocks have a strong roadmap in India because global drug makers are widening their use of Indian partners, and domestic demand for chronic therapies keeps growing. The main drivers are as follows. Outsourcing trend. Drug makers outsource discovery, development and manufacturing to cut cost and time. Chronic therapy growth. Diabetes, heart and other long-term conditions give branded drugs repeat demand. Integrated offer. Companies that cover several stages keep customers for longer. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Sai Life Sciences performed financially?
Ans. Revenue rose from Rs 898 crore in FY22 to Rs 2,242 crore in FY26, a compound annual growth rate of 25.7%. Net profit grew from Rs 170 crore in FY25 to Rs 349 crore in FY26, a rise of 105.1%. In the June 2026 quarter, revenue grew 10.2% year on year to Rs 558 crore, while net profit rose 21.2% to Rs 73.3 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.12 and a market capitalisation of Rs 29,679 crore. The stock trades at a P/E of 82.0, above the industry P/E of 36.0. Looking ahead, the roadmap is built on adding development and manufacturing capacity and moving more projects from discovery into late-stage and commercial supply. Customers tend to stay with a partner across the drug life cycle, which creates a durable order pipeline.
How has Eris Lifesciences performed financially?
Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.
How has Innova Captab performed financially?
Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.
What risks should investors check before buying pharma services stocks?
Ans. Investors should check a few risks before buying pharma services stocks. Customer concentration. A few large customers can account for much of the revenue. Regulatory audits. Plant inspections can affect supply and approvals. Prescription trends. Branded sales depend on doctor preference and competing launches. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma services stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.